Evaluation of a New Medical Device AL539 in Patients With Obstructive Apneas Sleep Syndrome

NCT ID: NCT01441622

Last Updated: 2014-06-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Continuous Positive Airway Pressure (CPAP) is the standard treatment in patients with Obstructive Sleep Apnea Syndrome (OSAS).

The goal of the study is to evaluate CPAP treatment duration recorded by the AL539 during attended in-hospital polysomnography in patients with Obstructive Sleep Apnea Syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients are patients with sleep apnea predominantly obstructive, with CPAP for at least 2 months, and requiring in-hospital night polygraphic record control.

The medical device was developed to determine:

* the duration of use of CPAP by the patient,
* the persistence of any respiratory abnormalities during treatment.

These two parameters are used to ensure that treatment is done correctly.

The use of the AL539 is expected to improve the home-monitoring of ventilation with CPAP.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Continuous Positive Airway Pressure (CPAP) AL539 Home-monitoring

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AL539

Device AL539

Group Type EXPERIMENTAL

AL539 (SRETT)

Intervention Type DEVICE

recording data with AL539 (SRETT)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AL539 (SRETT)

recording data with AL539 (SRETT)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Manufacturer name : SRETT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sleep apnea predominantly obstructive
* CPAP for at least 2 months and requiring in-hospital night polygraphic record
* Written informed consent form
* Able to read and write in French

Exclusion Criteria

* Ventilator with two levels of pressure
* CPAP breathing circuit non-compatible with the AL539
* Chronic respiratory disease
* Psychotropic treatment which may influence the respiratory parameters
* Acute rhinitis or acute nasopharyngitis
* Moderate or severe chronic heart failure
* CHEYNE-STOKES respiration
* Body mass index (BMI) \> 40
* Pregnant woman or woman of childbearing potential with a positive urinary pregnancy test
* Uncontrolled progressive disease
* Psychiatric disorders or regular user of drugs
* Participation in any interventional clinical trial within 30 days prior to selection
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Atlanstat

INDUSTRY

Sponsor Role collaborator

Air Liquide Santé International

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Damien LEGER, Pr

Role: PRINCIPAL_INVESTIGATOR

Hôpital Hôtel Dieu

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Hôtel DIEU - Centre du sommeil et de la Vigilance

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Leger D, Elbaz M, Piednoir B, Carron A, Texereau J. Evaluation of the add-on NOWAPI(R) medical device for remote monitoring of compliance to Continuous Positive Airway Pressure and treatment efficacy in obstructive sleep apnea. Biomed Eng Online. 2016 Feb 27;15:26. doi: 10.1186/s12938-016-0139-4.

Reference Type DERIVED
PMID: 26922498 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IDR CB / 2010-A00923-36

Identifier Type: OTHER

Identifier Source: secondary_id

ALMED-10-MD-030

Identifier Type: -

Identifier Source: org_study_id